Agilon Health (AGL) Cash & Equivalents (2020 - 2026)

Agilon Health has reported Cash & Equivalents for 7 years, with the latest figure at $140.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 2.22% year-over-year to $140.0 million; the trailing twelve-month figure through Mar 2026 stood at $140.0 million (up 2.22% YoY), and the FY2025 full-year result was $173.7 million, down 7.71% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $140.0 million, down from $173.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.0 billion in Q1 2022, with the low at $107.6 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $289.4 million across 5 years, with a median of $171.7 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 870.43% — and 2023, when it plunged 76.88%.
• Agilon Health's Cash & Equivalents stood at $465.3 million in 2022, then sank by 76.88% to $107.6 million in 2023, then jumped by 74.98% to $188.2 million in 2024, then decreased by 7.71% to $173.7 million in 2025, then declined by 19.41% to $140.0 million in 2026.
• The last three Cash & Equivalents figures came in at $140.0 million (Q1 2026), $173.7 million (Q4 2025), and $171.7 million (Q3 2025), per Business Quant data.